Convergence Investment Partners’s Quest Diagnostics DGX Stock Holding History

Convergence Investment Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,506	Closed	-$219K	–	239
2021 Q3	$219K	Buy	+1,506	New	+$220K	0.12%	176
2019 Q3	–	Sell	-8,990	Closed	-$915K	–	318
2019 Q2	$915K	Sell	8,990 -219	-2%	-$21K	0.22%	162
2019 Q1	$828K	Buy	+9,209	New	+$798K	0.18%	173
2018 Q2	–	Sell	-240	Closed	-$24K	–	468
2018 Q1	$24K	Buy	+240	New	+$24.6K	﹤0.01%	553
2016 Q4	–	Sell	-27,820	Closed	-$2.35M	–	332
2016 Q3	$2.35M	Buy	+27,820	New	+$2.34M	0.35%	103

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Convergence Investment Partners's DGX Position: Q4 2021 in Review

Convergence Investment Partners sold out of Quest Diagnostics (DGX) in Q4 2021, closing a stake of 1,506 shares — an estimated $219K sold.

Convergence Investment Partners first reported a position in DGX in Q3 2016 and held it in 5 quarters. The position peaked at $2.35M in Q3 2016. 905 funds tracked by Wall St. Rank hold DGX as of Q4 2021.

Convergence Investment Partners reported no remaining Quest Diagnostics position as of Q4 2021 after selling out during the quarter.
Convergence Investment Partners sold 1,506 Quest Diagnostics shares in Q4 2021, an estimated $219K.
Convergence Investment Partners first reported a position in Quest Diagnostics in Q3 2016 and held it in 5 quarters.
Convergence Investment Partners's Quest Diagnostics position peaked at $2.35M in Q3 2016.
905 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2021.

Based on Convergence Investment Partners's 13F filing for Q4 2021, filed 25 Jan 2022.